PMC:7571312 / 31048-31739 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T64","span":{"begin":224,"end":233},"obj":"Body_part"},{"id":"T65","span":{"begin":364,"end":367},"obj":"Body_part"},{"id":"T66","span":{"begin":371,"end":374},"obj":"Body_part"}],"attributes":[{"id":"A64","pred":"fma_id","subj":"T64","obj":"http://purl.org/sig/ont/fma/fma62852"},{"id":"A65","pred":"fma_id","subj":"T65","obj":"http://purl.org/sig/ont/fma/fma278683"},{"id":"A66","pred":"fma_id","subj":"T66","obj":"http://purl.org/sig/ont/fma/fma278683"}],"text":"Table 5 Protease Inhibition by 4\nprotease source % inhibition @ 10 μMa IC50 (μM)a\n3CLpro SARS CoV-1   0.004 ± 0.0003b\n3CLpro SARS CoV-2 0.00027 ± 0.0001b\ncathepsin B human 93 1.3 ± 0.1\ncathepsin D human 3 \u003e10\nleukocyte elastase human –31 \u003e10\nchymotrypsin human 8 \u003e10\nthrombin human –28 \u003e10\npepsin human –2 \u003e10\ncaspase 2 human –20 \u003e10\nHIV-1 HIV-1 0 \u003e10\nHCV HCV 16 \u003e10\nHRV HRV   1.7 ± 1\nhCoV 229E human   0.004 ± 0.0004\na See the Experimental Section for details on assay methods; the values were calculated from at least eight data points with at least two independent determinations.\nb For SARS CoV-1 and CoV-2 3CLpro, Ki values are reported here."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T76","span":{"begin":94,"end":98},"obj":"Disease"},{"id":"T77","span":{"begin":133,"end":137},"obj":"Disease"},{"id":"T78","span":{"begin":634,"end":638},"obj":"Disease"}],"attributes":[{"id":"A76","pred":"mondo_id","subj":"T76","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A77","pred":"mondo_id","subj":"T77","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A78","pred":"mondo_id","subj":"T78","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"Table 5 Protease Inhibition by 4\nprotease source % inhibition @ 10 μMa IC50 (μM)a\n3CLpro SARS CoV-1   0.004 ± 0.0003b\n3CLpro SARS CoV-2 0.00027 ± 0.0001b\ncathepsin B human 93 1.3 ± 0.1\ncathepsin D human 3 \u003e10\nleukocyte elastase human –31 \u003e10\nchymotrypsin human 8 \u003e10\nthrombin human –28 \u003e10\npepsin human –2 \u003e10\ncaspase 2 human –20 \u003e10\nHIV-1 HIV-1 0 \u003e10\nHCV HCV 16 \u003e10\nHRV HRV   1.7 ± 1\nhCoV 229E human   0.004 ± 0.0004\na See the Experimental Section for details on assay methods; the values were calculated from at least eight data points with at least two independent determinations.\nb For SARS CoV-1 and CoV-2 3CLpro, Ki values are reported here."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T297","span":{"begin":84,"end":85},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T298","span":{"begin":173,"end":174},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"},{"id":"T299","span":{"begin":176,"end":181},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T300","span":{"begin":210,"end":215},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T301","span":{"begin":244,"end":249},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T302","span":{"begin":274,"end":279},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T303","span":{"begin":298,"end":303},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T304","span":{"begin":322,"end":327},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T305","span":{"begin":348,"end":353},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T306","span":{"begin":435,"end":440},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T307","span":{"begin":460,"end":461},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T308","span":{"begin":627,"end":628},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"}],"text":"Table 5 Protease Inhibition by 4\nprotease source % inhibition @ 10 μMa IC50 (μM)a\n3CLpro SARS CoV-1   0.004 ± 0.0003b\n3CLpro SARS CoV-2 0.00027 ± 0.0001b\ncathepsin B human 93 1.3 ± 0.1\ncathepsin D human 3 \u003e10\nleukocyte elastase human –31 \u003e10\nchymotrypsin human 8 \u003e10\nthrombin human –28 \u003e10\npepsin human –2 \u003e10\ncaspase 2 human –20 \u003e10\nHIV-1 HIV-1 0 \u003e10\nHCV HCV 16 \u003e10\nHRV HRV   1.7 ± 1\nhCoV 229E human   0.004 ± 0.0004\na See the Experimental Section for details on assay methods; the values were calculated from at least eight data points with at least two independent determinations.\nb For SARS CoV-1 and CoV-2 3CLpro, Ki values are reported here."}

{"project":"LitCovid-sentences","denotations":[{"id":"T194","span":{"begin":0,"end":33},"obj":"Sentence"},{"id":"T195","span":{"begin":34,"end":85},"obj":"Sentence"},{"id":"T196","span":{"begin":86,"end":124},"obj":"Sentence"},{"id":"T197","span":{"begin":125,"end":162},"obj":"Sentence"},{"id":"T198","span":{"begin":163,"end":196},"obj":"Sentence"},{"id":"T199","span":{"begin":197,"end":223},"obj":"Sentence"},{"id":"T200","span":{"begin":224,"end":259},"obj":"Sentence"},{"id":"T201","span":{"begin":260,"end":287},"obj":"Sentence"},{"id":"T202","span":{"begin":288,"end":313},"obj":"Sentence"},{"id":"T203","span":{"begin":314,"end":336},"obj":"Sentence"},{"id":"T204","span":{"begin":337,"end":363},"obj":"Sentence"},{"id":"T205","span":{"begin":364,"end":384},"obj":"Sentence"},{"id":"T206","span":{"begin":385,"end":402},"obj":"Sentence"},{"id":"T207","span":{"begin":403,"end":423},"obj":"Sentence"},{"id":"T208","span":{"begin":424,"end":459},"obj":"Sentence"},{"id":"T209","span":{"begin":460,"end":626},"obj":"Sentence"},{"id":"T210","span":{"begin":627,"end":691},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Table 5 Protease Inhibition by 4\nprotease source % inhibition @ 10 μMa IC50 (μM)a\n3CLpro SARS CoV-1   0.004 ± 0.0003b\n3CLpro SARS CoV-2 0.00027 ± 0.0001b\ncathepsin B human 93 1.3 ± 0.1\ncathepsin D human 3 \u003e10\nleukocyte elastase human –31 \u003e10\nchymotrypsin human 8 \u003e10\nthrombin human –28 \u003e10\npepsin human –2 \u003e10\ncaspase 2 human –20 \u003e10\nHIV-1 HIV-1 0 \u003e10\nHCV HCV 16 \u003e10\nHRV HRV   1.7 ± 1\nhCoV 229E human   0.004 ± 0.0004\na See the Experimental Section for details on assay methods; the values were calculated from at least eight data points with at least two independent determinations.\nb For SARS CoV-1 and CoV-2 3CLpro, Ki values are reported here."}

{"project":"LitCovid-PubTator","denotations":[{"id":"778","span":{"begin":163,"end":174},"obj":"Gene"},{"id":"779","span":{"begin":337,"end":344},"obj":"Gene"},{"id":"780","span":{"begin":94,"end":102},"obj":"Species"},{"id":"781","span":{"begin":133,"end":143},"obj":"Species"},{"id":"782","span":{"begin":176,"end":181},"obj":"Species"},{"id":"783","span":{"begin":244,"end":249},"obj":"Species"},{"id":"784","span":{"begin":274,"end":279},"obj":"Species"},{"id":"785","span":{"begin":298,"end":303},"obj":"Species"},{"id":"786","span":{"begin":322,"end":327},"obj":"Species"},{"id":"787","span":{"begin":348,"end":353},"obj":"Species"},{"id":"788","span":{"begin":364,"end":369},"obj":"Species"},{"id":"789","span":{"begin":371,"end":376},"obj":"Species"},{"id":"790","span":{"begin":408,"end":417},"obj":"Species"},{"id":"791","span":{"begin":424,"end":433},"obj":"Species"},{"id":"792","span":{"begin":435,"end":440},"obj":"Species"},{"id":"793","span":{"begin":403,"end":406},"obj":"Species"},{"id":"796","span":{"begin":634,"end":642},"obj":"Species"},{"id":"797","span":{"begin":649,"end":654},"obj":"Species"}],"attributes":[{"id":"A778","pred":"tao:has_database_id","subj":"778","obj":"Gene:1508"},{"id":"A779","pred":"tao:has_database_id","subj":"779","obj":"Gene:834"},{"id":"A780","pred":"tao:has_database_id","subj":"780","obj":"Tax:694009"},{"id":"A781","pred":"tao:has_database_id","subj":"781","obj":"Tax:2697049"},{"id":"A782","pred":"tao:has_database_id","subj":"782","obj":"Tax:9606"},{"id":"A783","pred":"tao:has_database_id","subj":"783","obj":"Tax:9606"},{"id":"A784","pred":"tao:has_database_id","subj":"784","obj":"Tax:9606"},{"id":"A785","pred":"tao:has_database_id","subj":"785","obj":"Tax:9606"},{"id":"A786","pred":"tao:has_database_id","subj":"786","obj":"Tax:9606"},{"id":"A787","pred":"tao:has_database_id","subj":"787","obj":"Tax:9606"},{"id":"A788","pred":"tao:has_database_id","subj":"788","obj":"Tax:11676"},{"id":"A789","pred":"tao:has_database_id","subj":"789","obj":"Tax:11676"},{"id":"A790","pred":"tao:has_database_id","subj":"790","obj":"Tax:573824"},{"id":"A791","pred":"tao:has_database_id","subj":"791","obj":"Tax:11137"},{"id":"A792","pred":"tao:has_database_id","subj":"792","obj":"Tax:9606"},{"id":"A793","pred":"tao:has_database_id","subj":"793","obj":"Tax:169066"},{"id":"A796","pred":"tao:has_database_id","subj":"796","obj":"Tax:694009"},{"id":"A797","pred":"tao:has_database_id","subj":"797","obj":"Tax:2697049"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Table 5 Protease Inhibition by 4\nprotease source % inhibition @ 10 μMa IC50 (μM)a\n3CLpro SARS CoV-1   0.004 ± 0.0003b\n3CLpro SARS CoV-2 0.00027 ± 0.0001b\ncathepsin B human 93 1.3 ± 0.1\ncathepsin D human 3 \u003e10\nleukocyte elastase human –31 \u003e10\nchymotrypsin human 8 \u003e10\nthrombin human –28 \u003e10\npepsin human –2 \u003e10\ncaspase 2 human –20 \u003e10\nHIV-1 HIV-1 0 \u003e10\nHCV HCV 16 \u003e10\nHRV HRV   1.7 ± 1\nhCoV 229E human   0.004 ± 0.0004\na See the Experimental Section for details on assay methods; the values were calculated from at least eight data points with at least two independent determinations.\nb For SARS CoV-1 and CoV-2 3CLpro, Ki values are reported here."}